Key result
Aspirin hydrolysis velocity negatively correlates with platelet inhibition in atherosclerosis, particularly at low doses.
Why the study?
Does aspirin dose affect platelet aggregation and hydrolysis velocity in patients with atherosclerosis?
RCT
Double-blind
Randomized
Does aspirin dose affect platelet aggregation and hydrolysis velocity in patients with atherosclerosis?
The efficacy of low-dose aspirin in inhibiting platelet aggregation may be limited in patients with high aspirin hydrolysis velocity.
High hydrolysis velocity may limit low-dose aspirin antiplatelet efficacy in atherosclerosis; extends dose-dependent variability data for personalized dosing trials.
In a double blind, randomized trial, the effects of aspirin (1, 5, and 15 mg/kg) were compared with the changes in platelet aggregation at 6 and 24 hours after dosage. It is found that there is a negative correlation between aspirin hydrolysis velocity in blood and capability of aspirin to decrease platelet aggregation with ADP and collagen in patients with atherosclerosis. Relationship between these parameters depends on aspirin dosage. The correlation was more marked for low doses of aspirin. It is suggested that the effect of aspirin in low dosage on platelet aggregation might be ineffective in many patients without control of aspirin hydrolysis velocity in blood.
No takes yet. Share an insight, caveat, or question.
Akopov et al. (1992) conducted an RCT in Atherosclerosis. Aspirin was evaluated on Changes in platelet aggregation at 6 and 24 hours after dosage. Aspirin hydrolysis velocity in blood negatively correlated with its capability to decrease platelet aggregation in patients with atherosclerosis, particularly at low doses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: